-
Je něco špatně v tomto záznamu ?
Relevance of Antibody Validation for Flow Cytometry
T. Kalina, K. Lundsten, P. Engel
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
NLK
Free Medical Journals
od 2003 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2012-06-01 do Před 1 rokem
Wiley Free Content
od 2003 do Před 1 rokem
PubMed
31577065
DOI
10.1002/cyto.a.23895
Knihovny.cz E-zdroje
- MeSH
- indikátory a reagencie MeSH
- protilátky * MeSH
- průtoková cytometrie MeSH
- reprodukovatelnost výsledků MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Antibody reagents are the key components of multiparametric flow cytometry analysis. Their quality performance is an absolute requirement for reproducible flow cytometry experiments. While there is an enormous body of antibody reagents available, there is still a lack of consensus about which criteria should be evaluated to select antibody reagents with the proper performance, how to validate antibody reagents for flow cytometry, and how to interpret the validation results. The achievements of cytometry moved the field to a higher number of measured parameters, large data sets, and computational data analysis approaches. These advancements pose an increased demand for antibody reagent performance quality. This review summarizes the codevelopment of cytometry, antibody development, and validation strategies. It discusses the diverse issues of the specificity, cross-reactivity, epitope, titration, and reproducibility features of antibody reagents, and this review discusses the validation principles and methods that are currently available and those that are emerging. We argue that significant efforts should be invested by antibody users, developers, manufacturers, and publishers to increase the quality and reproducibility of published studies. More validation data should be presented by all stakeholders; however, the data should be presented in sufficient experimental detail to foster reproducibility, and community effort shall lead to the public availability of large data sets that can serve as a benchmark for antibody performance. © 2019 International Society for Advancement of Cytometry.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026759
- 003
- CZ-PrNML
- 005
- 20211026132632.0
- 007
- ta
- 008
- 211013s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/cyto.a.23895 $2 doi
- 035 __
- $a (PubMed)31577065
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kalina, Tomas $u CLIP-Childhood Leukemia Investigation Prague, Department of Pediatric Hematology and Oncology, 2nd Medical School, Charles University and University Hospital Motol, Prague, Czech Republic
- 245 10
- $a Relevance of Antibody Validation for Flow Cytometry / $c T. Kalina, K. Lundsten, P. Engel
- 520 9_
- $a Antibody reagents are the key components of multiparametric flow cytometry analysis. Their quality performance is an absolute requirement for reproducible flow cytometry experiments. While there is an enormous body of antibody reagents available, there is still a lack of consensus about which criteria should be evaluated to select antibody reagents with the proper performance, how to validate antibody reagents for flow cytometry, and how to interpret the validation results. The achievements of cytometry moved the field to a higher number of measured parameters, large data sets, and computational data analysis approaches. These advancements pose an increased demand for antibody reagent performance quality. This review summarizes the codevelopment of cytometry, antibody development, and validation strategies. It discusses the diverse issues of the specificity, cross-reactivity, epitope, titration, and reproducibility features of antibody reagents, and this review discusses the validation principles and methods that are currently available and those that are emerging. We argue that significant efforts should be invested by antibody users, developers, manufacturers, and publishers to increase the quality and reproducibility of published studies. More validation data should be presented by all stakeholders; however, the data should be presented in sufficient experimental detail to foster reproducibility, and community effort shall lead to the public availability of large data sets that can serve as a benchmark for antibody performance. © 2019 International Society for Advancement of Cytometry.
- 650 12
- $a protilátky $7 D000906
- 650 _2
- $a průtoková cytometrie $7 D005434
- 650 _2
- $a indikátory a reagencie $7 D007202
- 650 _2
- $a reprodukovatelnost výsledků $7 D015203
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Lundsten, Kelly $u BioLegend, Inc, San Diego, CA, USA
- 700 1_
- $a Engel, Pablo $u Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain
- 773 0_
- $w MED00013935 $t Cytometry. Part A : the journal of the International Society for Analytical Cytology $x 1552-4930 $g Roč. 97, č. 2 (2020), s. 126-136
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31577065 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026132638 $b ABA008
- 999 __
- $a ok $b bmc $g 1715491 $s 1147266
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 97 $c 2 $d 126-136 $e 20191002 $i 1552-4930 $m Cytometry. Part A $n Cytometry A $x MED00013935
- LZP __
- $a Pubmed-20211013